FREE TRIAL Receive 30 days of no-obligation access. SIGN UP
Vaccine attorneys are raising concerns about a planned HHS rule to establish a COVID-19 countermeasures injury table under the Countermeasures Injury Compensation Program, arguing that even if the table makes some claims easier to prove, CICP remains a less effective vehicle for compensating people who allege serious injuries than the National Vaccine Injury Compensation Program because of its limited transparency, narrower benefits and lack of a meaningful appeals process.
HHS’ latest regulatory agenda shows the administration intends to propose rules boosting alternative coverage, like association health plans and short-term plans, and update rules around employers’ ability to fund workers’ individual coverage via health reimbursement arrangements (ICHRAs), the administration also wants to implement the Affordable Care Act’s Section 1333 provision allowing state to establish compacts to sell insurance.
D.C. District Court Judge James Boasberg issued an order Friday (July 10) allowing the Federal Trade Commission to move ahead with a lawsuit against the World Professional Organization for Transgender Health in Texas, after he had previously blocked FTC from accessing certain documents in his own district upon concluding the agency was retaliating against WPATH for its support of gender-affirming care for minors.
Home care lobbyists are working with lawmakers to draft legislation to delay the inclusion of some product categories in durable medical equipment, prosthetics, & supplies (DMEPOS) competitive bidding for five years, as the lobbyists push the House to pass other pieces of home care legislation before Congress recesses in August.
A draft FDA rule published Friday (July 10) proposes to permit related drug manufacturing facilities in multiple locations to be registered as a single establishment, as well as revise the agency’s drug establishment registration and drug listing requirements to accord with the 2022 PREVENT Pandemics Act.
The HHS agency introduced by the Biden administration to accelerate cutting-edge health technologies announced its slate of award recipients for a $160 million project to advance gene editing technologies for rare diseases Thursday (July 9).
